文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症COVID-19患者感染SARS-CoV-2奥密克戎亚系JN.1的临床表型与结局:法国前瞻性多中心队列研究,2022年11月至2024年1月

Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
PubMed 文献 · Ann Intensive Care · 2024-06-28
一句话结论重症JN.1感染者较XBB更常肥胖、较少免疫抑制,但28天死亡率无显著差异(14.6% vs 22.0%,p=0.28)。

该研究为SEVARVIR前瞻性多中心观察性队列研究的子研究,纳入2022年11月17日至2024年1月22日法国40个ICU中年龄≥18岁、鼻咽拭子RT-PCR确诊SARS-CoV-2感染、因急性呼吸衰竭入住ICU的患者,比较JN.1组(56例)与XBB组(126例)的临床表型及28天死亡率。JN.1组肥胖比例更高(35.7% vs 20.8%,p=0.033),免疫抑制比例更低(20.4% vs 41.4%,p=0.010)。JN.1组28天死亡率为14.6%,与XBB组的22.0%无显著差异(p=0.28);校正混杂因素后JN.1感染与28天死亡率无显著关联(校正OR 1.06,95%CI 0.17–1.42;p=0.19)。两组ICU住院时长亦无显著差异(6.0 [3.5;11.0] vs 7.0 [4.0;14.0]天;p=0.21)。

要点

  • 重症JN.1感染者28天死亡率为14.6%,XBB组为22.0%,两组无显著差异(p=0.28)。
  • 校正肥胖、免疫抑制、年龄和SOFA评分后,JN.1感染与28天死亡率无显著关联(校正OR 1.06,95%CI 0.17–1.42;p=0.19)。
  • JN.1组肥胖比例高于XBB组(35.7% vs 20.8%,p=0.033),免疫抑制比例低于XBB组(20.4% vs 41.4%,p=0.010)。
  • JN.1组29.1%接受有创机械通气,87.5%接受地塞米松,14.5%接受托珠单抗,无患者接受单克隆抗体。
  • JN.1组仅1例(1.8%)需ECMO支持,XBB组0/126例(p=0.30);两组ICU住院时长无显著差异(6.0 [3.5;11.0] vs 7.0 [4.0;14.0]天;p=0.21)。

适用人群与场景

  • 年龄≥18岁、鼻咽拭子RT-PCR确诊SARS-CoV-2感染、因急性呼吸衰竭入住ICU的患者。
  • 研究纳入法国40个ICU中2022年11月17日至2024年1月22日收治的患者。

研究设计与关键结果

  • 研究类型:前瞻性多中心观察性队列研究(SEVARVIR研究子研究,NCT05162508),纳入40个法国ICU。
  • 样本量:JN.1组56例,XBB组126例,共182例。
  • JN.1组肥胖比例35.7% vs XBB组20.8%(p=0.033);JN.1组免疫抑制比例20.4% vs XBB组41.4%(p=0.010)。
  • JN.1组29.1%接受有创机械通气,87.5%接受地塞米松,14.5%接受托珠单抗,无患者接受单克隆抗体。
  • JN.1组1例(1.8%)需ECMO支持,XBB组0/126例(p=0.30)。
  • 主要终点:JN.1组28天死亡率14.6%,XBB组22.0%,无显著差异(p=0.28)。
  • 单变量及校正预设混杂因素(肥胖、免疫抑制、年龄、SOFA评分)的多变量分析均未发现JN.1感染与28天死亡率有统计学显著关联(校正OR 1.06,95%CI 0.17–1.42;p=0.19)。
  • ICU住院时长:JN.1组6.0 [3.5;11.0]天 vs XBB组7.0 [4.0;14.0]天,无显著差异(p=0.21)。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症JN.1感染患者与早期XBB亚系感染患者相比具有不同的临床表型,包括更常肥胖和较少免疫抑制。
  • 作者认为,与XBB相比,JN.1感染与更高的28天死亡率无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. However, no clinical data are available regarding critically-ill JN.1 COVID-19 infected patients.

METHODS: The current study is a substudy of the SEVARVIR prospective multicenter observational cohort study. Patients admitted to any of the 40 participating ICUs between November 17, 2022, and January 22, 2024, were eligible for inclusion in the SEVARVIR cohort study (NCT05162508) if they met the following inclusion criteria: age ≥ 18 years, SARS-CoV-2 infection confirmed by a positive reverse transcriptase-polymerase chain reaction (RT-PCR) in nasopharyngeal swab samples, ICU admission for acute respiratory failure. The primary clinical endpoint of the study was day-28 mortality. Evaluation of the association between day-28 mortality and sublineage group was conducted by performing an exploratory multivariable logistic regression model, after systematically adjusting for predefined prognostic factors previously shown to be important confounders (i.e. obesity, immunosuppression, age and SOFA score) computing odds ratios (OR) along with their corresponding 95% confidence intervals (95% CI).

RESULTS: During the study period (November 2022-January 2024) 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p = 0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p = 0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Only one JN-1 infected patient (1.8%) required extracorporeal membrane oxygenation support during ICU stay (vs 0/126 in the XBB group; p = 0.30). Day-28 mortality of JN.1-infected patients was 14.6%, not significantly different from that of XBB-infected patients (22.0%; p = 0.28). In univariable logistic regression analysis and in multivariable analysis adjusting for confounders defined a priori, we found no statistically significant association between JN.1 infection and day-28 mortality (adjusted OR 1.06 95% CI (0.17;1.42); p = 0.19). There was no significant between group difference regarding duration of stay in the ICU (6.0 [3.5;11.0] vs 7.0 [4.0;14.0] days; p = 0.21).

CONCLUSIONS: Critically-ill patients with Omicron JN.1 infection showed a different clinical phenotype than patients infected with the earlier XBB sublineage, including more frequent obesity and less immunosuppression. Compared with XBB, JN.1 infection was not associated with higher day-28 mortality.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. de Prost N, Audureau E, Guillon A, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024. Ann Intensive Care. 2024. PMID: 38940865. doi:10.1186/s13613-024-01319-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。